Addressing Unmet Needs in Myelofibrosis Management
Series Description:
Myelofibrosis (MF) is a rare and chronic bone marrow disorder characterized by the progressive replacement of normal bone marrow tissue with fibrous scar tissue. This fibrosis scar tissue disrupts the normal production of blood cells in the bone marrow, leading to various complications. This activity will assist clinicians in providing patient-centered care for patients with MF.
Learners will gain a greater understanding of pathophysiologic mechanisms of MF, the impact of this condition on patients’ QoL, limitations of current therapies, the latest data on emerging treatment options, and how to apply this information into practice with a patient-centric approach.Learning Objectives:
- Explain the pathophysiologic mechanisms involved in the development of MF and progression of the disease
- Describe the burden of disease and impact on quality of life for patients with MF and as a consequence of current treatments
- Identify current and future goals for managing MF based on therapeutic targets for improved overall survival
- Compare and contrast clinical data on new and emerging agents for myelofibrosis with a focus on improving QoL
- Identify strategies to prevent, monitor, and manage treatment-related adverse effects
- Recognize approaches to ensure shared decision-making and equitable care with patients
Moderators and/or Speakers, Institutions, and Credentials:
Aaron Gerds, MD, MS
Assistant Professor in Medicine
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH
Elizabeth Hexner, MD
Medical Director, Center for Cellular Immunotherapies
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Philadelphia, PA
Gabriela Hobbs, MD
Clinical Director, Leukemia Service
Massachusetts General Hospital
Boston, MA
Jeanne Palmer, MD
Vice Chair and Section Chief for Hematology
Program Director, Bone Marrow Transplant Program
Mayo Clinic Arizona
Phoenix, AZ
Target Audience:
Hematologists, hematologists/oncologists, hematology/oncology nurse practitioners, physician associates, and other health care professionals involved in the treatment and management of patients with myelofibrosis.